Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains an Outperform rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $42 to $46.
May 09, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll reaffirmed an Outperform rating on Revolution Medicines and increased the price target to $46 from $42.
The increase in price target by a reputable analyst like Robert Driscoll suggests a strong confidence in Revolution Medicines' future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100